Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6

Drug Metabolism and Disposition

Volumn 27, Issue 9, 1999, Pages 1078-1084

  Shin, Jae Gook ^a   Soukhova, Nadia ^a   Flockhart, David A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE;

ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DEMETHYLATION; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; ENZYME METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; REGRESSION ANALYSIS; TISSUE DISTRIBUTION;

ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; LIVER;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0032870729     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA. Woosley RL and Flockhart DA (1995) The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 57:662-669.
2. Boobis AR(1995) Prediction of inhibitory drug-drug interactions by studies in vitro, in Advances in Drug Metabolism in Man (Pacifici GM and Fracchia GN eds) pp 513-539, the European Commission, Luxembourg.
3. Broly F, Libersa CL, Lhermitte M, Bechtel P and Dupuis B (1989) Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 28:29-36.
4. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T and Ishizaki T (1993) Oxidative metabolism of omeprazole in human liver microsomes: Congregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266:52-59.
5. Desta Z, Kerbusch T and Flockhart DA (1999) Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizer of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 65:10-20.
6. Desta Z, Kerbusch T. Soukhova N, Richard E, Ko JW and Flockhart DA (1998) Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 285:428-437.
7. Dinovo EC, Bost RO, Sunshine I and Gottschalk LA (1978) Distribution of thioridazine and its metabolites in human tissues and fluids obtained postmortem. Clin Chem 24:1828-1830.
8. Eiermann B, Endel G, Johansson I, Zanger UR and Bertilsson L (1997) The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 44:439-446.
9. Ereshefsky L (1996) Pharmacokinetics and drug interactions: Update for new antipsychotics. J Clin Psychiatry 57(Suppl 11):12-25.
10. Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D and Vickers AE (1998) The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: Implications for drug-drug interaction and pharmacological activity of the main metabolite. Drug Metab Dispos 26:802-811.
11. Forsman A, Larsson M, Lundborg H and Renstrom P (1981) On the distribution and elimination of haloperidol in cholecystectomized patients. Eur J Drug Metab Pharmacokinet 6:249-253.
12. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Robert GC and Wolf CR (1997) Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain.
13. Goff DC and Baldessarini RJ (1993) Drug interactions with antipsychotic agents. J Clin Psychopharmacol 13:57-67.
14. Gorski JC, Jones DR, Wrighton SA and Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 48:173-182.
15. Halliday RC, Jones DR, Smith DA, Kitteringham NR and Park BK (1995) An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 40:369-378.
16. Hardman JG, Limbird LE, Molinoff PB, Rudden RW and Gilman AG (1995) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., McGraw-Hill, New York.
17. Hiroi T, Imaoka S, Chow T, Yabusaki Y and Funae Y (1997) Specific binding of 1-[2-(diphenylmethoxy) ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. Biochem Pharmacol 53:1937-1939.
18. Javaid JI (1994) Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol 34:286-295.
19. Ko J-W, Soukhova N, Thacker D, Chen P and Rockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitor of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862.
20. Maynard GL and Soni P (1996) Thioridazine interferences with imipramine metabolism and measurement. Ther Drug Monit 18:729-731.
21. Meyer MC, Baldessarini RJ, Goff DC and Centorrino F (1996) Clinically significant interactions of psychotropic agents with antipsychotic drugs. Drug Saf 15:333-346.
22. Michalets EM (1998) Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84-112.
23. Mulsant BH, Foglia JP, Sweet RA, Rosen J, Lo KH and Pollock BG (1997) The effect of perphenazine on the concentration of nortriptyline and its hydroxy metabolites in older patients. J Clin Psychopharmacol 17:318-321.
24. Murray M and Reidy CF (1989) In vitro inhibition of hepatic drug oxidation by thioridazine: Kinetic analysis of the inhibition of cytochrome P-450 isoform-specific reactions. Biochem Pharmacol 38:4359-4365.
25. Nelson JC and Jatlow PI (1980) Neuroleptic effect on desipramine steady-state plasma concentrations. Am J Psychiatry 137:1232-1234.
26. 3H]GBR-12935 binding proteins. Arch Biochem Biophys 276:424-432.
27. Otton SV, Crewe HK, Lennard MS, Tucker GT and Woods HF (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 247:242-247.
28. Pan LP, Wijnant P, De Vriendt C, Rosseel MT and Belpaire FM (1997) Characterization of the cytochrome P450 isozymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 44:557-564.
29. Pollard HB, Menard R, Brandt HA, Pazolzs CJ, Creutz CE and Ramu A (1978) Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal Biochem 86:761-763.
30. Relling MV, Aoyama T, Gonzalez FJ and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-447.
31. Ring BJ, Binkley SN, Vandenbraden M and Wrighton SA (1996) In vitro interaction of the antipsychotic agent olanzapine with human cytochrome P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41:181-186.
32. Riskin TS (1994) Effect of clozapine on plasma nortriptyline concentration. Pharmacopsychiatry 27:41-42.
33. Rosholm JU, Hallas J and Gram LF (1994) Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in outpatients - A prescription database study. Br J Clin Pharmacol 37:533-538.
34. Segel IH (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons, Inc., New York.
35. Spina E, Martines C, Caputi AP, Cobaleda J, Pinas B, Carrillo JA and Benitez J (1991) Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 41:467-470.
36. Sproule BA, Naranjo CA, Bremner KE and Hassan PC (1997) Selective serotonin reuptake inhibitors and CNS drug interactions: A critical review of the evidence. Clin Pharmacokinet 33:454-471.
37. Strobl GR, von Kruednener S, Stockigt J, Guengerich FP and Wolf T (1993) Development of a pharmacophore for inhibition of human liver cytochrome P4502D6: Molecular modeling and inhibition studies. J Med Chem 36:1136-1145.
38. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Turkey RH, Quattrochi LC, Gelboin HV and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
39. Taylor D and Lader M (1996) Cytochromes and psychotropic drug interactions. Br J Psychiatry 168:529-532.
40. Tyndale RF, Sunahara S, Inaba T, Kalow W, Gonzalez FJ and Niznik HB (1991) Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): Potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. J Pharmacol Exp Ther 40:63-68.
41. Von Bahr C, Spina E, Birgersson C, Ericsson O, Göransson M, Henthorn T and Sjöqvist F (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 34:2501-2505.
42. von Moltke LL, Greenblatt DA, Grassi JG, Granda BW, Schmider J, Harmatz JS and Shader RI (1998) Reevaluation of the specificity of dextromethorphan as an index substrate. Clin Pharmacol Ther 63:227.
43. Zhang Y, Gou X, Lin ET and Benet LZ (1998) Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Dispos 26:360-366.